Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression The enrollment goal of 125 patients was met. Median age was 46 years (range, 21-65 years), ...
Clinical, Economic Benefits of Pegfilgrastim Biosimilars as Prophylactic Against Febrile Neutropenia
In patients with intermediate- to high-risk, use of pegfilgrastim biosimilars could optimize management of FN risk. Use of biosimilar pegfilgrastim as a prophylaxis in patients with cancer and a high ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results